Evidence map›Paper›PMID 30560488›Full record

ArticleJournal of thrombosis and thrombolysis2019

Venous thromboembolism in patients with cancer undergoing surgical exploration.

Samantha M Ruff, Kathryn T Weber, Adam Khader, Charles Conte, Alan Kadison, James Sullivan, John Wang, Raza Zaidi, Gary B Deutsch

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Samantha M RuffDepartment of General Surgery, Long Island Jewish Hospital, Northwell Health, 270-05 76th Ave, Queens, NY, 11040, USA. Samantha.marilyn.ruff@gmail.com.
Kathryn T WeberDepartment of General Surgery, Long Island Jewish Hospital, Northwell Health, 270-05 76th Ave, Queens, NY, 11040, USA.
Adam KhaderDepartment of General Surgery, Long Island Jewish Hospital, Northwell Health, 270-05 76th Ave, Queens, NY, 11040, USA.
Charles ConteDivision of Surgical Oncology, Northwell Health, 450 Lakeville Rd, Lake Success, NY, 11042, USA.
Alan KadisonDivision of Surgical Oncology, Northwell Health, 450 Lakeville Rd, Lake Success, NY, 11042, USA.
James SullivanDivision of Surgical Oncology, Northwell Health, 450 Lakeville Rd, Lake Success, NY, 11042, USA.
John WangDivision of Surgical Oncology, Northwell Health, 450 Lakeville Rd, Lake Success, NY, 11042, USA.
Raza ZaidiDivision of Surgical Oncology, Northwell Health, 450 Lakeville Rd, Lake Success, NY, 11042, USA.
Gary B DeutschDivision of Surgical Oncology, Northwell Health, 450 Lakeville Rd, Lake Success, NY, 11042, USA.
Northwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignancy and surgery are both independent risk factors for venous thromboembolism (VTE) events. The current NCCN guidelines recommend VTE prophylaxis for up to 28 days after major abdominal or pelvic surgery for malignancy. We set out to evaluate the rate and timing of VTEs among patients with gastric, pancreatic, colorectal, and gynecologic malignancies who underwent surgery. We performed a retrospective review of the NSQIP database (2005-2013) focusing on patients with gastric, colorectal, pancreatic, and gynecologic malignancies. Our primary endpoint was a diagnosis of VTE within 30 days of surgery. We analyzed 128,864 patients in this study. On multivariable analysis, patients with pre-operative sepsis (OR 2.36, CI 2.04-2.76, p < 0.001), disseminated cancer (OR 1.73, CI 1.55-1.92, p < 0.001), congestive heart failure (OR 1.69, CI 1.25-2.28, p = 0.001), gastric cancer (OR 1.3, CI 1.09-1.56, p = 0.004), and pancreatic cancer (OR 1.2, CI 1.03-1.30, p = 0.021) were more likely to have a VTE. Of patients who had a VTE event, 34% occurred after discharge from surgery (gastric: 25%, colorectal 34%, pancreatic 31%, gynecologic malignancy 42%). Our study demonstrates that patients who undergo an operation for malignancy with pre-operative sepsis, disseminated cancer, congestive heart failure, gastric cancer, or pancreatic cancer are more likely to develop a VTE within 30 days of their operation. Of those patients who developed a VTE, approximately one-third occurred after discharge during a 30 day post-operative period. This data supports that further studies are needed to determine the appropriate length of post-operative VTE chemoprophylaxis in patients with cancer.

Indexed as

AgedDatabases, FactualDigestive System NeoplasmsDigestive System Surgical ProceduresFemaleGenital Neoplasms, FemaleGynecologic Surgical ProceduresHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesCancerDeep vein thrombosisDischargeNeoplasmSurgeryVenous thromboembolism

Identifiers

PMID30560488
OpenAlexW2903844833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.